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Key points:  
1. Delirium is a major public health concern, and research on pathophysiological mechanisms 
is urgently needed.  
2. Some biochemical changes in the brain are to an extent reflected in the cerebrospinal fluid 
(CSF) and in recent years there has been a blossoming of studies examining CSF as a method 
of studying the pathophysiology of delirium.  
3. The 22 studies identified in this review reveal a small but growing literature, in which 
many of the important hypotheses in delirium pathogenesis have been examined, but from 
which few firm conclusions can currently be drawn. Nevertheless, the overall interpretation of 
the literature supports the vulnerable brain concept.  
4. A concerted effort is now required to standardise several aspects of the methodology and 
reporting of these studies, in order to advance this highly promising direction in delirium 
research. 
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Abstract  
 
Objective In recent years there has been a blossoming of studies examining cerebrospinal 
fluid (CSF) as a method of studying the pathophysiology of delirium. We systematically 
reviewed the literature for CSF studies in delirium and provide here a summary of the 
implications for our understanding of delirium pathophysiology. We also summarise the 
methods used for CSF analysis and discuss challenges and implications for future studies.  
 
Methods In this systematic review we screened MEDLINE, EMBASE, PsycINFO, Web of 
Science, PubMed and the Cochrane Library for articles on CSF biomarkers in delirium, 
published to September 3rd 2016. Studies were required to use DSM or ICD criteria for 
delirium, or a validated tool. We excluded case reports. There were no other restrictions on 
study type.  
 
Results We identified 3280 articles from our initial search and 22 articles were included in 
this review. All studies were prospective, including over 400 patients with delirium and 700 
controls. More than 70 different biomarkers were studied. Studies could not be compared with 
each other for meta-analysis because of their heterogeneity, and varied widely in their risk of 
bias and quality assessments.  
 
Conclusions The 22 studies identified in this review reveal a small but growing literature, in 
which many of the important hypotheses in delirium pathogenesis have been examined, but 
from which few firm conclusions can currently be drawn. Nevertheless, the overall 
interpretation of the literature supports the vulnerable brain concept, that is that biomarker 
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evidence of for example Alzheimer’s disease pathology and/or neuroinflammation is 
associated with delirium.  
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Introduction 
Delirium is a common, serious and dramatic complication of acute medical illness associated 
with increased mortality and morbidity (Inouye et al., 2013, Witlox et al., 2010). Recent 
evidence suggests that delirium predicts dementia in previously cognitively intact patients, 
and is linked with accelerated decline in those with existing dementia (Davis et al., 2012, 
Krogseth et al., 2016, Davis et al., 2017). Thus, delirium is a major public health concern, and 
research on pathophysiological mechanisms is urgently needed.  
In recent years there has been a blossoming of studies examining cerebrospinal fluid (CSF) 
for insights into the pathophysiology of delirium. CSF, a clear fluid surrounding the brain and 
providing mechanical support, also carries nutrients and signalling molecules to neurons and 
helps the clearance of metabolites into the blood (Johanson et al., 2008, Louveau et al., 2015). 
The main advantage utilising CSF to measure markers of central nervous system (CNS) 
changes is that it communicates freely with the brain interstitial fluid that bathes the neurons. 
Some biochemical changes in the brain are thus reflected in the CSF, which may be regarded 
as an accessible, albeit imperfect, sample of the brain interstitial fluid (Blennow et al., 2010). 
This provides an advantage over blood, as confirmed in studies of neurodegenerative 
disorders (Blennow et al., 2010). Further, CSF has low protease activity and most molecules 
do not change upon sampling if the sample is uncontaminated by blood (Johanson et al., 
2008). The main disadvantage is that lumbar puncture (LP) is an invasive procedure, and 
there are obvious ethical and practical difficulties in obtaining CSF specimens for research 
purposes from patients with delirium. Several recent CSF delirium studies have overcome this 
problem by exploiting the valuable opportunity afforded by spinal anaesthetic administration 
for surgical procedures, especially hip fracture surgery. 
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In 2011, Hall et al published a systematic literature review of the eight existing studies of CSF 
in delirium(Hall et al., 2011). The 2011 review highlighted a paucity of research in this area; 
no clear conclusions emerged regarding delirium pathophysiology, with more detailed studies 
needed. This review serves as an update. We aimed to identify the current published literature 
examining CSF in delirium, and ask, do CSF biomarker concentrations relate to delirium 
incidence, severity, duration or subtype. We summarise what the current literature reveals 
about delirium pathophysiology, and also the methods used for CSF analysis and discuss 
challenges and implications for future studies.  
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Methods  
Search strategy and selection criteria 
We are reporting this systematic review according to the PRISMA guidelines (Liberati et al., 
2009). We searched MEDLINE, EMBASE, PsycINFO, Web of Science, PubMed and the 
Cochrane Library for studies published in English or Norwegian to September 3rd 2016. 
Additionally we hand searched the bibliographies of relevant articles, performed a forward 
citation search in Web of Science for all studies examined, and contacted experts in the field 
via the European Delirium Association. We used terms including Delirium or Acute 
Confusional State, and Cerebrospinal Fluid or Lumbar Puncture (see Appendix 1 for full 
search strategy and Appendix 2 for the study protocol).  
Inclusion criteria were (i) that delirium was diagnosed by Diagnostic and Statistical Manual 
of Mental Disorders (DSM III; DSM IIIR; DSM IV, DSM 5) or International Classification of 
Diseases (ICD) criteria, or a method based upon this and (ii) that we could extract data on 
biomarker findings in CSF in delirium. Exclusion criteria were (i) case reports (no other 
restrictions on study type) and (ii) studies involving delirium tremens or hepatic 
encephalopathy, or where neuropsychiatric Systematic Lupus Erythematosus was the primary 
cause of delirium.  
 
Data extraction and assessment of study quality and risk of bias 
RJH and LOW independently performed the search and identified articles for full text review. 
Included studies were agreed by consensus and data were extracted by RJH, LOW and EC. 
We recorded (a) study design and provenance, (b) number and characteristics of patients and 
controls and comparability of patient and control groups, (c) method used to diagnose 
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delirium, (d) delirium severity, motor subtype and duration, (e) aetiology of delirium, (f) 
presence and method of assessment for underlying dementia, (g) method of obtaining CSF, 
(g) biomarkers studied, (i) preanalytical and analytical laboratory methodology (j) main study 
findings, (k) statistical significance, and (l) statistical methods. Risk of bias was assessed 
according to the RoBANS tool (Kim et al., 2013), with pre-determined criteria for low or high 
risk for each domain. We considered the principal confounding factor to be dementia. Risk of 
bias was assessed by RJH, LOW and EC independently, and agreed by consensus. 
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Results 
We identified 3280 articles from our initial search and 2352 remained after removal of 
duplicates (Figure 1). 194 full-text articles were assessed for eligibility (Appendix 3), and 22 
articles were included in the systematic review. The included articles reported data from nine 
research groups, including several collaborations (Table 1). All studies collected data on 
delirium status prospectively, although most collected CSF only once (with the exception of 
(Koponen and Riekkinen, 1990) and (Hirsch et al., 2016). Over 400 patients with delirium 
and 700 controls were studied, although many are included in more than one article. There is 
some overlap of biomarkers studied by different research groups, and the differing results are 
discussed. Studies could not be compared to each other for meta-analysis due to study 
heterogeneity. Baseline characteristics of the included studies are presented in Table 1, the 
main findings in Table 2, and the results of the risk of bias assessment plus additional quality 
comments in Table 3. Several studies examined biomarker relationships with delirium 
severity, few assessed motor subtype and none reported delirium duration. Overall, risk of 
bias varied, with smaller exploratory studies generally having higher risk, and more recent 
larger studies lower risk. Many had a risk of selection bias, limited control of confounding 
variables and inadequate blinding of outcome assessments. Risk of publication bias was 
difficult to assess as other biomarkers may have been measured and not reported. Studies 
generally measured delirium well, and reported all their outcome variables. Details of the 
methods reported are summarized in Supplementary Table 1. A narrative summary of the 
findings is presented below. 
 
[insert Figure 1 , Table 1 and Table 2 around here] 
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Risk markers of delirium 
Dementia neuropathology markers  
Dementia neuropathology markers were measured in three studies of patients undergoing 
orthopaedic surgery. 
Witlox et al examined β-amyloid1-42 (Aβ42), total-tau (T-tau) and phosphorylated tau (P-tau) 
in hip fracture patients (Witlox et al., 2011). There were no statistically significant differences 
in levels of these markers between those with or without post-operative delirium (preoperative 
delirium was excluded).  
Idland et al also studied hip fracture patients (Idland et al., 2016). They found that, in patients 
without dementia, delirium was associated with lower CSF Aβ42 levels and higher T-tau 
levels and lower ratios of Aβ42 to t-tau and p-tau. In patients with dementia, CSF biomarker 
levels did not differ between those with and without delirium. The authors suggest that a 
possible explanation for the discrepancy with Witlox et al is that the biomarker levels in the 
Dutch cohort were much closer to normal levels, indicating less AD pathology. 
Xie et al studied elective arthroplasty patients (Xie et al., 2014). They found no significant 
difference in CSF Aβ42/tau ratio or Aβ40/tau ratio between groups with and without delirium. 
When they examined quartiles of the Aβ/tau ratios, they found a higher incidence of delirium 
in those in the lowest quartile for both ratios.  
 
Disease markers of delirium 
Neurotransmitters and hormones 
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Levels of neurotransmitter precursors, metabolites and metabolising enzymes, and potentially 
neuroactive hormones have been measured in several studies, although few have been 
analysed in more than one study. 
 
Somatostatin-like immunoreactivity (SLI) and Beta-endorphin-like immunoreactivity (BLI) 
The first CSF study was published in 1990 (Koponen and Riekkinen, 1990). An aetiologically 
heterogeneous group of older patients with delirium underwent a morning fasting LP on the 
day following their index admission, at two weeks after admission, and at one year and four 
years. Their control group was from a Healthy Ageing study. For the whole delirium group, 
they found a reduction in mean SLI level at index, two weeks, one year and four years 
(Koponen et al., 1994b) and a reduction in mean BLI at index, two weeks and one 
year(Koponen and Riekkinen, 1990).  
 
Monoamine precursors and metabolites 
Koponen et al found that the principal serotonin metabolite 5-hydroxyindoleacetic acid (5-
HIAA) was higher in the subgroups with delirium superimposed on vascular dementia or no 
CNS disease(Koponen et al., 1994c). The levels stayed high at two weeks and one year in 
both groups.  
Watne et al published analyses of 5-HIAA and aromatic amino acids, which are precursors for 
monoamines(Watne et al., 2016). They found that both phenylalanine and tyrosine (dopamine 
and noradrenaline precursors) and tryptophan (serotonin precursor) were higher in patients 
with delirium. In patients without dementia, 5-HIAA was also highest in delirium, paralleling 
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the increase in tryptophan. Patients with dementia had lower levels of most amino acids 
compared to patients without dementia. Analyses stratified by dementia status, however, 
revealed that delirium was associated with higher levels of the same amino acids in both 
strata. Notably, the correlation between serum and CSF amino acids levels was poor. 
Ramirez-Bermudez et al examined homovanillic acid (HVA, a dopamine metabolite) in a 
cohort of patients with acute neurological symptoms requiring LP for a clinical indication 
(Ramirez-Bermudez et al., 2008). This cohort was younger and had a high proportion of CNS 
infections (43/51 patients), and HIV infection (16/51 patients). Although HVA was not 
significantly different between those with and without delirium, it was higher in patients with 
psychotic features such as hallucinations and delusions.  
 
Acetylcholine 
Koponen et al found no association between delirium and acetylcholinesterase (AChE), the 
principle enzyme responsible for metabolising acetylcholine (Koponen et al., 1994a) in the 
delirious group as a whole. However, there was a fall in levels of AChE between the two-
week and one year time-points in the delirium subgroups with AD, multi-infarct dementia and 
hyperkinetic delirium, and a small but non-significant reduction in levels of AChE in the 
group with no CNS disease. Watne et al analysed anticholinergic activity (AA) in patients 
with acute hip fracture from Oslo and Edinburgh(Watne et al., 2014) and found that AA was 
not significantly different in delirium.  
 
Cortisol 
13 
 
Pearson et al found cortisol levels to be higher in those with delirium than those without, in a 
small cohort of patients with acute hip fracture (Pearson et al., 2010). 
 
 
Inflammation 
Neuroinflammation has been assessed in several studies. All studies included orthopaedic 
patients (hip fracture in all except for elective surgery in Hirsch (Hirsch et al., 2016)).  
 
Cytokines and chemokines 
MacLullich et al measured six cytokines, but only interleukin (IL) -8 (33/36 samples) and IL-
6 (3/36 samples) were above the detection limit (MacLullich et al., 2011). IL-8 was higher in 
patients with delirium at any stage.  
Westhoff et al measured 41 different cytokines and chemokines but only 16 were detectable 
in more than 50% of the samples (Westhoff et al., 2013). Fms-like tyrosine kinase-3 (Flt-3L), 
IL-1ra and IL-6 were significantly lower in patients with postoperative delirium (preoperative 
delirium was excluded). They detected, but found no difference in levels of, IL-8. The authors 
suggest that the findings could be interpreted that delirium is the result of a dysfunctional 
inflammatory state, where reduced anti-inflammatory mediators play a more important role 
than an increased pro-inflammatory activity.  
Cape et al measured several inflammatory markers and a marker of astroglial activation (Glial 
Fibrillary Acidic Protein, GFAP) in patients recruited in Edinburgh and Amsterdam (Cape et 
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al., 2014). The investigators found that IL-1β was elevated in those with incident delirium, 
and IL-1ra was elevated in prevalent delirium. The CSF:serum ratio of IL-1β was higher in 
the delirium group. GFAP was not significantly different between groups. IFN-γ and IGF-1 
were not detected in CSF and IL-1β was detected in low concentrations. This study supports a 
role for the IL-1 family in delirium. The higher CSF:serum ratio of IL-1β, with no correlation 
between the two, suggests a CNS source of IL-1β.  
Neerland et al examined C-reactive protein (CRP), IL-6 and soluble IL-6 receptor (sIL-6R). 
In patients without prefracture cognitive impairment, CSF CRP was higher in delirium 
(Neerland et al., 2016). There were no significant differences in delirium in IL-6 or sIL-6R. 
The authors suggest that different pathophysiological mechanisms are important in different 
subgroups of patients. In particular, neuroinflammation may be more important in cohorts 
other than those with hip fracture.  
A recent study reported longitudinal changes in CSF and plasma in ten patients undergoing 
elective knee surgery (Hirsch et al., 2016). An indwelling spinal catheter was placed at the 
time of spinal anesthesia and removed after 24 hours. Plasma and CSF were collected 
preoperatively and at three, six and 18 hours postoperatively. Only one patient developed 
delirium, and CSF levels of the pro-inflammatory cytokines IL-6, IL-8 and monocyte 
chemotactic protein (MCP)-1 showed a persistent increase in this patient. Intriguingly, levels 
of several pro- and anti-inflammatory cytokines changed significantly postoperatively 
compared to baseline, and these changes were often more pronounced in CSF than plasma.  
 
Neopterin 
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Neopterin, a biomarker of cell-mediated immunity and oxidative stress, has been measured in 
one study (Hall et al., 2016). Those who developed delirium after hip fracture had higher 
levels compared to those who did not become delirious. Neopterin levels were highest in 
patients with delirium superimposed on dementia and lowest in patients free from both 
conditions. The authors conclude that these findings support the neuroinflammation 
hypothesis in delirium, and that delirium and dementia may have an additive effect.   
 
Blood-cerebrospinal fluid barrier 
Hov et al assessed the blood-cerebrospinal fluid barrier integrity in hip fracture patients with 
Q-albumin (the ratio of CSF albumin to serum albumin) (Hov et al., 2016). The majority of 
patients (88%), had intact blood-cerebrospinal fluid barrier integrity, but all patients with 
barrier dysfunction (n=14) had delirium (n=11) or subsyndromal delirium (n=3). The authors 
conclude that blood-cerebrospinal fluid barrier dysfunction might be important for delirium, 
but it is not a prerequisite for delirium to develop. 
 
Proteomics 
Poljak et al recruited patients in two centres, Sydney (medical patients) and Edinburgh (hip 
fracture patients) (Poljak et al., 2014). Of the 273 proteins identified, 16 were dysregulated in 
eight or more delirium subjects across both cohorts. Several proteins involved in the 
inflammatory response were also upregulated in the majority of those with delirium.  
Another proteomics study (Westhoff et al., 2015) included two different Dutch cohorts with 
acute hip fracture (preoperative delirium was excluded), for derivation and validation of 
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changes found with proteomics. Of the 17 proteins identified as different in the proteomics 
analysis between those with and without delirium, none were confirmed as different with 
immunoassay in the validation cohort.  
 
End products of delirium 
Markers of neuronal cell death 
Elderly medical patients with prolonged delirium and a control group of outpatients with AD 
but no delirium were studied in (Caplan et al., 2010). CSF lactate, protein, glucose, S100 
calcium-binding protein B (S100B, a marker of CNS injury and astrogliosis) and neuron-
specific enolase (NSE) were measured. They found higher CSF lactate in the delirium group, 
lower NSE, higher protein, and no difference in S100B and glucose. Of note, the group with 
delirium was acutely unwell compared to the outpatient dementia group; therefore differences 
may be due to the general effects of acute illness rather than delirium.  
S100B has also been measured in hip fracture patients in two different studies. Hall et al 
found that S100B concentrations were higher in those with preoperative delirium, although 
there was no difference between those with and without delirium at any stage during the 
perioperative period (Hall et al., 2013). Another found no significant difference in S100B 
between patients with or without (predominantly postoperative) delirium (Beishuizen et al., 
2015).  
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Discussion 
The 22 studies identified in this review reveal a small but growing literature, in which many 
of the important hypotheses in delirium pathogenesis have been examined, but from which 
few firm conclusions can currently be drawn. The observational nature of all studies means 
causality cannot be established. The populations studied are heterogeneous, and studies varied 
in their risk of bias. We will now briefly discuss what this literature suggests regarding 
delirium pathophysiology.  
 
Risk markers 
Dementia is one of the strongest risk factors for delirium (Ahmed et al., 2014, Fong et al., 
2015). However, of the three studies that examined whether levels of established CSF markers 
for dementia were associated with risk of delirium only Idland et al showed a convincing 
relationship (Idland et al., 2016).  These findings may be related to the presence of incipient 
dementia, and future studies should take this into account. 
 
Disease markers of delirium 
Several of the studies support the hypothesis of neurotransmitter imbalance in delirium. The 
monoamines (dopamine, serotonin, noradrenaline) have important roles in attention and 
cognition, cognitive domains affected in delirium (Maldonado, 2013). The results in 
(Koponen et al., 1994c) support an excess of serotonin in delirium. The findings of increased 
levels of precursor amino acids in (Watne et al., 2016) suggest a downstream role for 
serotonin and for a generally higher monoaminergic tone in delirium. The association of high 
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dopamine metabolites with psychotic features in (Ramirez-Bermudez et al., 2008) supports a 
role in these symptoms of delirium, if not the whole syndrome. These findings have potential 
therapeutic implications and replication studies would be valuable. 
Loss of somatostatin signaling appears to have a role in dementia and transient loss may be 
implicated in delirium (Koponen et al., 1994b). There may be a fall in beta-endorphin 
signaling in delirium, but it is difficult to conclude that these changes are related to delirium 
rather than dementia (Koponen and Riekkinen, 1990). 
The findings in (Pearson et al., 2010) support the hypothesis that delirium is associated with 
elevated CNS cortisol levels.  
The neuroinflammatory hypothesis of delirium is a leading hypothesis, whereby a brain made 
vulnerable by neurodegenerative disease or ageing responds to peripheral inflammatory 
stimuli with a greater central inflammatory response, manifesting in exaggerated sickness 
behavior and delirium(Cunningham and Maclullich, 2013). In order to test this hypothesis in 
human studies, animal modelling (Cunningham et al., 2005, Godbout and Johnson, 2006) and 
hypothesis papers(Cerejeira et al., 2010) would predict that CSF IL-1, IL-6 and TNF-α should 
be elevated and IL-10 should be reduced in delirium. Elevated IL-1β was found in (Cape et 
al., 2014), with a higher ratio in CSF:serum, but it was not detected in (MacLullich et al., 
2011) nor (Westhoff et al., 2013). Since IL-1β is often hard to detect, its endogenous 
antagonist IL-1ra could be seen as a marker of recent IL-1β activity, as it is usually released 
after IL-1β to limit the inflammatory response(Allan et al., 2005). Westhoff et al found lower 
CSF IL-1ra levels in those about to develop delirium, whereas Cape et al found higher CSF 
IL-1ra levels in those with active delirium, possibly indicating that a lower baseline level 
increases the risk of developing delirium whereas during active delirium the higher levels may 
indicate either an endogenous response to an initial spike of IL-1β or a neuroprotective 
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response to the insult of delirium or the inflammatory and traumatic response. IL-6 was 
reduced in (Westhoff et al., 2013), not significantly different in (Neerland et al., 2016), and 
elevated in the sole patient with delirium in the Hirsch longitudinal study(Hirsch et al., 2016). 
TNF-α and IL-10 were both not detected in (MacLullich et al., 2011), and not significantly 
different (in small numbers) in (Westhoff et al., 2013). More indirectly the findings of the 
Poljak proteomics analysis that several of the proteins involved in the inflammatory response 
are upregulated in delirium also supports this notion(Poljak et al., 2014) and the finding by 
(Hall et al., 2016) that neopterin is highest in delirium superimposed on dementia lend some 
support to the idea that peripheral inflammatory insults may lead to an exaggerated central 
inflammatory response. However, the Westhoff proteomics study highlights the difficulties in 
this research area, with none of the candidate findings validated(Westhoff et al., 2015).  
Examining the evidence so far, one does not find a great deal to support the 
neuroinflammatory hypothesis of delirium, however it has not been refuted and many of the 
studies examining the key biomarkers have been small, with low detection levels. Delirium 
aetiology, timing of CSF sampling and underlying dementia neuropathology are potential 
reasons for the conflicting findings in the published literature. 
 
 
End products of delirium 
The finding of raised CSF lactate suggests that a disruption of the brain’s normal aerobic 
metabolism, perhaps resulting from ischaemia or hypoglycaemia, may be involved in delirium 
(Caplan et al., 2010). S100B was found to be elevated in those with active delirium after hip 
fracture (Hall et al., 2013), but not in medical patients with active delirium compared to 
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patients with dementia who were not acutely unwell (Caplan et al., 2010), nor in a third study 
in hip fracture patients with predominantly post-operative delirium (Beishuizen et al., 2015). 
In the latter study, the highest levels were in those with active delirium, highlighting that 
timing of sampling may be crucial. It is therefore unclear whether delirium is associated with 
astrigliosis or CNS damage. NSE was also lower in patients with delirium, contradicting such 
a hypothesis.  
[insert Table 3 around here] 
 
Delirium severity, subtype and timing of sampling 
Increasing delirium severity was associated with lower Aβ40/tau and Aβ42/tau ratios(Xie et 
al., 2014), higher HVA(Ramirez-Bermudez et al., 2008), lactate and NSE levels(Caplan et al., 
2010). In those without prior cognitive impairment, higher anticholinergic activity (Watne et 
al., 2014)and higher neopterin levels(Hall et al., 2016) were also associated with more severe 
delirium. There were no clear relationships between any of the biomarkers and delirium 
subtype. Timing of CSF sampling according to different phases of delirium was associated 
with different biomarker findings. CSF collection before delirium was associated with 
reduced IL-6, IL-1ra, Flt-3L(Westhoff et al., 2013), increased IL-1β(Cape et al., 2014), 
neopterin(Hall et al., 2016) and amino acid levels(Watne et al., 2016), and a low Aβ/tau 
ratio(Xie et al., 2014) conferred an increased risk of delirium. Collection during delirium was 
associated with reduced BLI(Koponen and Riekkinen, 1990) and SLI(Koponen et al., 1994b), 
increased IL-1ra(Cape et al., 2014), neopterin(Hall et al., 2016), lactate, protein(Caplan et al., 
2010), α1-glycoprotein(Poljak et al., 2014) and S100B(Beishuizen et al., 2015), lower 
NSE(Caplan et al., 2010) and in those without prior cognitive impairment, higher 
CRP(Neerland et al., 2016) and 5-HIAA(Watne et al., 2016).  
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Methodological issues 
Several of the studies could have been influenced by bias or confounding. Sample sizes were 
generally small. More recent collaborative studies collecting CSF at the onset of spinal 
anaesthetic have been larger, with lower risk of bias, but several included the same 
participants as in previous published articles. A diverse range of populations was studied, and 
generally patients with delirium were frailer, older, and more often had dementia. There is 
likely to be a high proportion of unrecognised dementia in the cohorts of patients with hip 
fracture and elderly medical inpatients. A further potential confounding factor in these 
heterogeneous groups of patients is the underlying precipitants of delirium.  
Serum values were reported in eleven studies. Interestingly, the direction of change in 
markers measured in both CSF and serum was sometimes at odds, illustrating the limitations 
in using analyses in blood to measure biochemical changes in the brain. The timing of 
sampling may be crucial; there may be different pathophysiological processes occurring in a 
patient who is not yet delirious, compared to new active delirium or prolonged delirium. 
Some authors have attempted to separate these groups, whereas in some studies all these 
phases are included as cases. Given that levels of biomarkers may be fleeting, and may 
change during different phases of the delirium syndrome, longitudinal sampling of CSF might 
shed more light on the complex relationship between biomarkers and delirium.  
 
In addition to timing, other pre-analytical variables may affect the results, with differences in 
the handling of CSF samples possibly contributing to the heterogeneity of results. Several 
potential variables of interest highlighted by work in the AD biomarker field are outlined in 
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Table 4. Analysis methods are outlined in Table 1. Whilst proteomic technologies and 
automated assays are increasingly frequently employed, enzyme-linked immunosorbent assay 
(ELISA)-based technologies remain the cornerstone of many delirium studies and analytical 
factors are also therefore still very relevant. All authors specified the kits used as a minimum. 
Several authors specified that analyses were undertaken by a single researcher at the same 
time point (thus decreasing laboratory practice variability). Analysis of samples in duplicate 
or triplicate is inconsistently reported, as are coefficients of variation (CV). Analytical 
variation is often high at low concentrations close to the analytical sensitivity of the assay and 
results may therefore be uncertain for some low abundant cytokines.  
This review was limited to studies published in English or Norwegian. Despite our extensive 
search, we might have missed eligible articles. As the authors of this review have been 
involved in several of the recent published articles, it might make us less objective on the 
faults of those articles. A strength is that we have insisted on formal delirium diagnosis by 
DSM or ICD criteria, or a method based upon this.  
 
Challenges and implications for future research 
CSF research in delirium faces several significant challenges. Care must be taken with 
potential participants who may lack capacity to consent to participation in such studies (Holt 
et al., 2008), and in particular when an invasive investigation such as CSF examination is 
proposed. Since 2010, many studies have taken the approach of collecting CSF 
opportunistically from patients undergoing spinal anaesthetic for surgery. Hip fracture 
patients are the most studied group. With delirium and dementia being prevalent in this 
population, we believe this will continue to be an important model for CSF delirium research 
in the future. An important limitation with all studies recruiting acutely admitted patients is 
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however the lack of opportunity to do objective cognitive testing before admission. Where 
there is potential concomitant dementia, it is very difficult to determine whether observed 
changes are related to acute delirium or confounded by underlying dementia pathology 
(Inouye and Ferrucci, 2006). Studies including elective patients can readily involve pre-
operative cognitive testing, but the prevalence of delirium is much lower. Also, no patients 
will have ongoing delirium in studies of elective patients so CSF analyses are limited to 
giving information regarding risk factors for delirium.   
It is important to avoid being too restrictive in performing LP for research purposes in 
delirium. LP is safe with post-LP headache being the only significant side-effect (less 
common in the elderly) (Duits et al., 2016).  Additionally, LP is sometimes carried out in the 
investigation of delirium, when certain primary brain disorders are suspected. Therefore, with 
sufficient care and selection of patients, we believe that studies of the CSF in delirium need 
not be restricted to opportunistic use of clinical samples or only where spinal anaesthesia is 
being performed. 
Future studies need to be informed by prior research, clearly report baseline characteristics of 
all subjects, and ensure blinding wherever possible. In order to carry out subgroup analyses, 
which are clearly necessary, larger patient cohorts are needed with standardised and detailed 
methods of recording of predisposing and precipitating factors. Standardised, detailed 
assessment of delirium presence as well its severity is essential, including (where possible) 
ascertainment of the presence or absence of psychotic features, the motoric subtypes, and the 
presumed aetiologies including where drug toxicity is a likely major factor. This will allow 
additional exploration of pathophysiological subtypes. Standardisation of the collection and 
handling of CSF will facilitate exchange of samples between centres. Ideally more 
generalisable populations of medical and surgical patients should be studied. Information 
about prior cognitive status is important, and should always be collected in studies recruiting 
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acutely admitted patients, through documentation of known prior dementia, and use of an 
informant questionnaire. Details regarding our recommendations for future studies are given 
in Table 4.  
 
[insert Table 4 around here] 
 
Conclusion 
In recent years there has been a blossoming of studies examining CSF in delirium. The 
heterogeneity of the studies preclude firm conclusions regarding the pathophysiology of 
delirium.Nevertheless, the overall interpretation of the literature supports the vulnerable brain 
concept, that is that biomarker evidence of, for example AD pathology and/or 
neuroinflammation is associated with delirium. A concerted effort is now required to 
standardise several aspects of the methodology and reporting of these studies, in order to 
advance this highly promising avenue of delirium research. 
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Figure 1. Study selection 
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Study / provenance Design / setting Biomarker(s) studied 
(Method used) 
Causes of 
delirium 
Age 
Mean or 
median  
Sex (% 
male) 
Cases Controls Timing of CSF 
sampling 
N delirious at 
LP 
Koponen et al(Koponen 
et al., 1994a, Koponen 
et al., 1994c, Koponen 
et al., 1994b, Koponen 
and Riekkinen, 1990) 
Finland 
Prospective 
cohort study, 
with external 
control group  
 
Psychogeriatric 
Hospital 
SLI (RIA) 
BLI (RIA) 
5-HIAA (HPLC)  
AChE (colorimetric 
method) 
Heterogeneous Cases: 75 
Controls: 
72 
Cases: 42  
Controls: 
39  
n=67 for SLI  
n=69 for other 
biomarkers  
n=58 at 2 weeks 
n=33 at 1 year 
n=11 at 4 years 
 
% with dementia:  
Possible Alzheimer’s 
dementia: N=14 
Multi-infarct dementia: 
N=39 
Parkinson’s disease: 
N=3 
No CNS disease N=13 
(psychiatrist diagnosis 
using appropriate 
criteria) 
Cognitive decline based 
on MMSE: mild N=4, 
moderate N=25, severe 
N=40 
n=13 
for SLI, 5-HIAA, AChE 
n=19 for BLI 
 
 
 
% with dementia: 0% 
Baseline: during 
delirium 
69/69 
 
2 weeks: during 
or after delirium 
14/58 
 
1 year: after 
delirium 
0/33 
 
4 years: after 
delirium 
0/11 
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Ramirez-Bermudez et 
al(Ramirez-Bermudez 
et al., 2008) 
Mexico 
Prospective 
cohort study 
 
General 
Hospital 
HVA (HPLC) Primarily acute 
CNS infection 
Whole 
sample: 
36 
Whole 
sample: 
55 
n=31 
 
Documented dementia 
excluded 
n=20 
 
Documented dementia 
excluded 
During delirium 
(within 24h of 
neuropsychologi
cal testing) 
31/31  
Caplan et al(Caplan et 
al., 2010) 
Australia  
Prospective 
cohort study 
 
General 
Hospital 
Lactate, NSE, S100B, 
Glucose, Protein 
(ELISA for S100B 
and NSE, in-house 
laboratory for lactate, 
protein and glucose) 
Heterogeneous, 
acute medical 
illness 
Cases: 82 
Controls: 
81 
Not stated n=20 
 
% with dementia: not 
stated (mean IQCODE 
3.7) 
 
n=20 
 
% with dementia: 100 
(Alzheimer’s dementia) 
During delirium 
(>5 days 
duration) 
20/20 
Pearson et al(Pearson 
et al., 2010) 
Scotland 
Prospective 
cohort study 
 
General 
Hospital 
Cortisol (RIA for 
plasma levels, ELISA 
for CSF levels) 
Hip fracture and 
consequent 
surgery 
Cases: 81 
Controls: 
81 
Whole 
sample: 
25  
n=7 
 
Documented dementia 
excluded 
n=13 
 
Documented dementia 
excluded 
Number 
delirious at 
collection not 
stated 
MacLullich et 
al(MacLullich et al., 
2011) 
Scotland and the 
Netherlands 
Prospective 
cohort study 
 
General 
Hospital 
TNF-α, IL-1β, IL-6, 
IL-8, IL-10 and IL-
12p70  
(Cytometric bead 
array) 
Hip fracture and 
consequent 
surgery 
 Not stated n=15  
 
% with dementia: not 
stated (7 in whole 
sample) 
n=21 
 
% with dementia: not 
stated (7 in whole 
sample) 
Before and 
during delirium, 
grouped 
together for 
statistical 
analysis 
9/36 
Witlox et al(Witlox et 
al., 2011) 
The Netherlands 
Prospective 
cohort study 
nested within a 
randomised 
controlled trial 
 
Aβ42, t-tau, p-tau 
(ELISA) 
Hip fracture and 
consequent 
surgery 
Cases: 85 
Controls: 
82 
Cases: 33 
Controls: 
33 
n=30 
 
 
n=46 
 
 
Before delirium 
0/76 
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General 
Hospital 
% with dementia: 64 
(defined as IQCODE > 
3.6) 
% with dementia: 16 
(defined as IQCODE > 
3.6) 
Hall et al(Hall et al., 
2013) 
Scotland 
Prospective 
cohort study 
 
General 
Hospital 
S100B (ELISA) Hip fracture and 
consequent 
surgery 
Cases: 81 
Controls: 
79 
Cases: 37  
Controls: 
27 
n=19 
% with dementia: 32 
(defined as IQCODE > 
3.44) 
 
n=26 
% with dementia: 0 
(defined as IQCODE > 
3.44) 
 
Before and 
during delirium 
8/45 
Westhoff et al(Westhoff 
et al., 2013) 
The Netherlands 
Prospective 
cohort study 
nested within a 
randomised 
controlled trial 
General 
Hospital 
Panel of 42 cytokines 
and chemokines 
(Luminex) 
Hip fracture and 
consequent 
surgery 
Cases: 85 
Controls: 
83 
Cases: 30 
Controls: 
32 
n=23 
 
% with dementia: 62 
(defined as IQCODE > 
3.6) 
n=38 
 
% with dementia: 11 
(defined as IQCODE > 
3.6) 
Before delirium 
0/61 
Cape et al(Cape et al., 
2014) 
Scotland and the 
Netherlands 
Prospective 
cohort study 
 
General 
Hospital 
IL-1β, IL-1ra, IGF-1, 
GFAP, IFN-γ  
(ELISA) 
Hip fracture and 
consequent 
surgery 
Cases: 81 
Controls: 
81 
Cases: 26   
Controls: 
25 
n=19 
 
% with dementia: 41 
(defined as IQCODE > 
3.44) 
 
n=24 
 
% with dementia: 4 
(defined as IQCODE > 
3.44) 
 
Before and 
during delirium 
8/43 
 
Poljak et al(Poljak et 
al., 2014) 
Australia and Scotland 
Prospective 
cohort study 
 
General 
Hospital 
Proteomics Heterogeneous, 
acute medical 
illness (Australia) 
Hip fracture and 
consequent 
surgery (Scotland) 
Cases: 82 
Controls:8
2  
Cases: 60   
Controls: 
30  
n=17 
 
% with dementia: not 
stated (mean IQCODE 
4.0 in Sydney group and 
3.3 in Edinburgh group) 
 
n=8 normal control 
n=17 Alzheimer’s 
dementia 
During delirium 
17/42 
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Watne et al(Watne et 
al., 2014) 
Norway and Scotland 
Prospective 
cohort study, 
part of cohort 
nested within 
randomised 
controlled trial 
 
General 
Hospital 
Anticholinergic 
activity (muscarinic 
radio receptor 
bioassay) 
Hip fracture and 
consequent 
surgery 
Cases: 85 
Controls: 
83 
Cases: 29 
Controls: 
21 
n=72 
 
% with dementia: 65 
(defined as IQCODE > 
3.44) 
 
n=79 
 
% with dementia: 13 
(defined as IQCODE > 
3.44) 
 
Before and 
during delirium 
38/151 
Xie et al(Xie et al., 
2014) 
USA 
Prospective 
cohort study 
 
General 
Hospital 
Aβ40, Aβ42, t-tau, 
Aβ40/t-tau ratio, 
Aβ42/t-tau ratio 
(ELISA) 
Hip or knee 
arthroplasty 
surgery 
Whole 
group: 71 
Not stated n=31 
 
Documented dementia 
excluded 
 
n=122 
 
Documented dementia 
excluded 
Before delirium 
0/153 
Beishuizen et 
al(Beishuizen et al., 
2015) 
The Netherlands  
Prospective 
cohort study 
General 
Hospital 
S100B (ELISA) Hip fracture and 
consequent 
surgery 
Cases: 86 
Controls: 
83 
Not stated n=15  
 
% with dementia: 27 
(defined as IQCODE > 
3.4) 
 
n=51 
 
% with dementia: 22 
(defined as IQCODE > 
3.4) 
 
 
Before and 
during delirium 
2/66 
Westhoff et al(Westhoff 
et al., 2015) 
The Netherlands 
Prospective 
cohort study 
General 
Hospital 
Proteomics for the 
derivation cohort 
Immunoassays for the 
validation cohort 
Hip fracture and 
consequent 
surgery in 
Alkmaar 
(derivation 
cohort) and 
Amsterdam 
(validation 
cohort) 
Derivation 
cohort: 83 
Validation 
cohort: 88 
Derivation 
cohort: 32  
Validation 
cohort: 29 
 
Derivation cohort n=19 
Validation cohort n=11 
 
% with dementia: not 
stated, but 26 % in 
whole derivation cohort  
and 25 % in whole 
validation cohort 
Derivation cohort n=34 
Validation cohort n=41 
Before delirium 
0/105 
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(defined as IQCODE > 
3.4) 
Hall et al(Hall et al., 
2016) 
Norway and Scotland 
Prospective 
cohort study, 
part of cohort 
nested within 
randomised 
controlled trial 
General 
Hospital 
Neopterin (HPLC) Hip fracture and 
consequent 
surgery 
Cases: 85 
Controls: 
82 
Cases: 30  
Controls: 
33  
n=64 
 
% with dementia: 63 
(defined as IQCODE > 
3.44) 
 
 
n=75 
 
% with dementia: 13 
(defined as IQCODE > 
3.44) 
 
 
Before and 
during delirium 
35/139 
Hirsch et al(Hirsch et 
al., 2016) 
USA 
Prospective 
cohort pilot 
study; 
longitudinal 
sampling over 
24h 
General 
Hospital 
17 cytokines +  Aβ42 
and Aβ40 (ELISA 
and Luminex) 
Major knee 
surgery 
Whole 
sample: 
70 
Whole 
sample: 
70  
n=1 delirium 
n=6 POCD 
 
Impaired cognition 
excluded 
 
n=3 
 
 
Impaired cognition 
excluded 
Before delirium 
/ POCD 
0/10 
Hov et al(Hov et al., 
2016) 
Norway 
Prospective 
cohort study, 
nested within 
randomised 
controlled trial 
General 
Hospital 
Blood-CSF barrier 
(assessed CSF/serum 
albumin ratio).  
Serum albumin: 
colorimetric assay 
CSF albumin: 
immunoturbidimetric 
assay 
Hip fracture and 
consequent 
surgery 
Cases: 85 
Controls: 
83  
Cases: 30  
Controls: 
20  
n=69  
 
% with dementia: 72 
(consensus diagnosis) 
 
 
n=51 
 
% with dementia: 3 
(consensus diagnosis) 
 
 
Not stated 
Idland et al(Idland et 
al., 2016) 
Norway  
Prospective 
cohort study, 
nested within 
randomised 
controlled trial 
Aβ42, t-tau, p-tau, 
Aβ42/t-tau ratio, 
Aβ42/p-tau ratio 
(INNOTEST ELISA) 
Hip fracture and 
consequent 
surgery 
Cases: 86 
Controls: 
84 
Cases: 30  
Controls: 
22  
n=70 
 
% with dementia: 77 
(consensus diagnosis) 
n=59 
 
% with dementia: 17 
(consensus diagnosis) 
Before and 
during delirium 
43/129 
(preoperative 
delirium status 
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General 
Hospital 
 
 
 
 
missing for 
N=5) 
 
Neerland et 
al(Neerland et al., 
2016) 
Norway and Scotland 
Prospective 
cohort study, 
part of cohort 
nested within 
randomised 
controlled trial 
General 
Hospital 
CRP, IL6, sIL6R 
(ELISA) 
Hip fracture and 
consequent 
surgery 
Cases: 85 
Controls: 
83 
Cases: 
30 %  
Controls: 
20 
 
n=71 
 
% with dementia: 65 
(defined as IQCODE > 
3.44) 
 
 
n=78 
 
% with dementia: 23 
(defined as IQCODE > 
3.44) 
 
Before and 
during delirium 
38/151 
Watne et al(Watne et 
al., 2016) 
Norway 
Prospective 
cohort study, 
nested within 
randomised 
controlled trial 
General 
Hospital 
Aminoacids and 
monoamine 
metabolites (HPLC) 
Hip fracture and 
consequent 
surgery 
Cases: 86 
Controls: 
84 
Cases: 30 
Controls: 
29  
n=53 
 
% with dementia: 66 
(consensus diagnosis) 
 
 
 
n=24 
 
% with dementia: 13 
(consensus diagnosis) 
 
 
Before and 
during delirium  
29/77 
(preoperative 
delirium status 
missing for 
N=3) 
Table 1. Baseline characteristics  of  included studies.  
5-HIAA - 5-Hydroxyindole-acetic acid. Aβ40 - Amyloid-β 1-40. Aβ42 - Amyloid-β 1-42. AChE - Acetyl-cholinesterase. BLI - Beta Endorphin-like immunoreactivity. CNS - central nervous 
system. ELISA - enzyme-linked immunosorbent assay. GFAP - Glial Fibrillary Acidic Protein. HPLC - High-performance liquid chromatography. HVA - Homovanillic acid. IL – interleukin. 
IFN-γ – Interferon gamma. IGF – insulin like growt factor. NSE - Neuron-specific enolase. POCD – Post operative cognitive dysfunction. P-tau - phosphorylated tau. RIA – Radioimmunoassay. 
sIL6R - soluble IL-6 receptor. S100B - S100 calcium-binding protein B. SLI - Somatostatin-like immunoreactivity. TNF – tumor necrosis factor. T-tau – total tau.  
 
 
 
 
36 
 
 
 
Risk markers of delirium 
Study, 
biomarkers 
measured 
Main findings at baseline 
Direction of change Cases 
Mean (SD) or median (range) 
or (IQR) 
Controls 
Mean (SD) or median 
(range) or (IQR) 
p-value Delirium 
severity 
Delirium 
subtype 
Witlox et al(Witlox 
et al., 2011) 
Aβ42, t-tau, p-tau 
Aβ42 no different 
t-tau no different 
p-tau no different 
631 pg/ml (500 - 985) 
306 pg/ml (231--389) 
72 pg/ml (51 - 81) 
755 pg/ml (567-1031) 
325 pg/ml (246 -523) 
70 pg/ml (59 - 96) 
0.21 
0.75 
0.55 
Not 
measured 
Not 
measured 
Idland et al(Idland 
et al., 2016) 
Aβ42, t-tau, p-tau 
↓ Aβ42 in delirium in subgroup without prefracture dementia 
↑ t-tau in delirium in subgroup without prefracture dementia 
No difference in biomarker findings between groups with 
prevalent, incident and never delirium 
310 ng/l (125 – 633) 
505 ng/l (187 – 1266)  
489 ng/l (133 – 1086) 
351 ng/l (133 – 808) 
0.006 
0.02 
Not 
measured 
Not 
measured 
Xie et al(Xie et al., 
2014) 
Aβ40, Aβ42, t-tau 
Aβ40/t-tau ratio no different 
Aβ42/t-tau ratio no different 
↑ Delirium incidence in lowest quartile of Aβ40/tau ratio vs. 
other 3 quartiles 
↑ Delirium incidence in lowest quartile of Aβ42/tau ratio vs. 
other 3 quartiles 
More severe delirium in lowest quartile of Aβ40/tau and 
Aβ42/tau ratios 
Preoperative Aβ40/tau and Aβ42/tau ratios negatively 
correlated with postoperative MDAS score, including after 
adjustment for age and gender 
12.2 (8.1-14.8) 
1.3 (0.7-1.9) 
32% 
32% 
12.6 (9.6-16.1) 
1.4 (1.0-2.1) 
17% 
17% 
0.241 
0.192 
0.048 
0.048 
MDAS 
 
Not 
measured 
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Disease markers of delirium 
Study, 
biomarkers 
measured 
Main findings at baseline 
Direction of change Cases 
Mean (SD) or median (range) 
or (IQR) 
Controls 
Mean (SD) or median 
(range) or (IQR) 
p-value Delirium 
severity 
Delirium 
subtype 
Koponen et 
al(Koponen and 
Riekkinen, 1990) 
BLI 
↓ BLI in whole delirious group 
↓ BLI in delirious group with no CNS disease 
12.5pg/ml (3.0) 
12.4pg/ml (3.8) 
15.2pg/ml (2.8) 
15.2pg/ml (2.8) 
<0.001 
<0.05 
Severity of 
cognitive 
decline only 
(MMSE) 
No 
difference 
between 
hypoactive, 
hyperactive 
or mixed  
Koponen et 
al(Koponen et al., 
1994b) 
SLI 
↓ SLI in whole delirious group 
↓ SLI in delirious group with no central nervous system 
(CNS) disease 
26.2pg/ml (8.8) 
25.9pg/ml (6.4) 
37.6pg/ml (9.8) 
37.6pg/ml (9.8) 
<0.001 
<0.001 
Severity of 
cognitive 
decline only 
(MMSE) 
No 
difference 
between 
hypoactive, 
hyperactive 
or mixed 
Koponen et al () 
5-HIAA 
No difference in whole delirious group 
↑ 5-HIAA in delirious group with no CNS disease  
↑ 5-HIAA in delirious group with multi-infarct dementia 
172.3 nmol/l (125.8) 
168.9 nmol/l (56.9) 
174.6 nmol/l (87.7) 
118.1 nmol/l (34.9) 
118.1 nmol/l (34.9) 
118.1 nmol/l (34.9) 
>0.05 
<0.05 
<0.05 
Severity of 
cognitive 
decline only 
(MMSE) 
No 
difference 
between 
hypoactive, 
hyperactive 
or mixed 
Watne et al(Watne 
et al., 2016) 
Amino acids and 
monoamine 
metabolites 
↑ Aminoacid precursors of monoamines in delirium  
Tryptophan (in those without dementia) 
Tyrosine (in those without dementia) 
Phenylalanine (in those without dementia) 
↑ 5HIAA in delirium in subgroup without dementia 
Amino acid levels tended to be highest in incident delirium 
 
1.1 μmol/l (0.7 – 1.5) 
8 μmol/l (5 – 11) 
14 μmol/l (9 – 19) 
170 nmol/l (119 – 261) 
 
0.8 μmol/l (0.6 – 1.0) 
5 μmol/l (4 – 7) 
9 μmol/l (7 – 13) 
138 nmol/l (111 – 156) 
 
0.042 
0.028 
0.014 
0.048 
Not 
measured 
Not 
measured 
38 
 
Ramirez-Bermudez 
et al(Ramirez-
Bermudez et al., 
2008) 
HVA 
HVA not significantly different in delirium vs non-delirium 
HVA ↑ in those with hallucinations 
HVA correlates with DRS score  (r=0.334, p=0.017) 
300.8nM (36-1915.7) 
436.54nM (36-1915.7) 
 
231.65nM (36-1062.3) 
192.39nM (36-1062.3) 
 
0.108 
0.018 
 
DRS Trend to 
higher HVA 
in agitated 
subtype 
Koponen et 
al(Koponen et al., 
1994a) 
AChE 
↑ AChE in delirious patients who died during follow-up vs. 
rest of cohort 
 
22.0nmol/ml/min (8.0) 
 
18.1nmol/ml/min (5.0) 
 
0.005 
 
Severity of 
cognitive 
decline only 
(MMSE) 
No 
difference 
between 
hypoactive, 
hyperactive 
or mixedNot 
Watne et al(Watne 
et al., 2014) 
Anticholinergic 
activity 
Anticholinergic activity no different in Oslo cohort 
Anticholinergic activity no different in Edinburgh cohort 
No difference in AA levels between prevalent, incident, 
subsyndromal or never delirium 
Trend to higher CSF AA in more severe delirium in 
Edinburgh cohort 
CSF AA positively correlated with MDAS score in pooled 
cohort without prefracture cognitive impairment (Spearman 
rho=0.59, p=0.002) 
0.39pmol/mL (0.11-0.82) 
0.36pmol/mL (0.18-0.67) 
0.48pmol/mL (0.24-0.98) 
0.31pmol/mL (0.10-0.75) 
0.26 
0.93 
Oslo: 
MDAS 
Edinburgh: 
DRS-R98, 
MDAS 
rated 
retrospectiv
ely  
Not 
measured 
Pearson et 
al(Pearson et al., 
2010) 
Cortisol 
↑ CSF cortisol in delirium vs controls 
 
63.9nmol/L (40.4-102.1) 
 
31.4nmol/L (21.7-43.3) 
 
0.029 
 
MDAS used 
but no 
comment on 
relationship 
Not 
measured 
MacLullich et 
al(MacLullich et 
al., 2011) 
TNF-α, IL-1β, IL-6, 
IL-8, IL-10, IL-
12p70 
↑ IL-8 in delirium vs. controls 
TNF-α, IL-1β, IL-10 and IL-12p70 not detected 
69.8pg/ml (47.9-125.6) 
 
39.6pg/ml (28.0-64.6) 
 
0.003 
 
Not 
measured 
Not 
measured 
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Westhoff et 
al(Westhoff et al., 
2013) 
Panel of 42 
cytokines and 
chemokines 
↓ Flt-3L in delirium vs. controls 
↓ IL-1ra in delirium vs. controls 
↓ IL-6 in delirium vs.controls  
IL-8 no different 
(only 16 of 42 cytokines detectable in more than 50% of the 
samples).  
 
16.54pg/ml (12.2-20.2) 
2.90pg/ml (2.9-6.9) 
0.21pg/ml (0.1-0.7) 
25.25pg/ml (19.4-37.6) 
 
20.16pg/ml (18.2-29.5) 
6.90pg/ml (2.9-6.9) 
0.99pg/ml (0.2-2.2) 
28.40pg/ml (22.7-42.5) 
 
0.021 
0.032 
0.005 
0.308 
 
DRS-R98 
used but no 
comment on 
relationship 
between 
biomarkers 
and delirium 
severity 
Not 
measured 
Cape et al(Cape et 
al., 2014) 
IL-1β, IL-1ra, IGF-
1, IFN-γ, GFAP 
CSF IL-1β higher in incident delirium vs. prevalent delirium 
vs. never delirium 
 
CSF IL-1ra higher in prevalent delirium vs. incident delirium 
vs. never delirium 
 
 
GFAP no different in delirium 
 
IGF-1 and IFN-γ not detected 
Prev 0.84pg/ml (0.49-1.57)  
Inc 1.74pg/ml (1.02-1.74) 
Prev  70.75pg/ml (65.63-
73.01) 
Inc 31.06pg/ml (28.12-35.15) 
Prev 0.81ng/ml (0.33-1.31) 
Inc 0.61ng/ml (0.46-0.76) 
 
Never 0.66pg/ml (0-1.02) 
 
Never 33.98 pg/ml (28.71-
43.28) 
 
Never 0.45ng/ml (0.31-
0.86)  
0.03 
 
0.04 
 
 
0.58 
Not 
measured 
Not 
measured 
Neerland et 
al(Neerland et al., 
2016) 
CRP, IL-6, sIL-6R 
↑ CRP in delirium in subgroup without prefracture cognitive 
impairment 
IL-6 no different 
sIL-6R no different 
CSF CRP highest in group without prior cognitive 
impairment with prevalent (preoperative) delirium 
Trend towards highest CSF sIL-6R in group with prior 
cognitive impairment and incident (postoperative) delirium 
0.05 μg/ml (0.02 – 0.12) 
4.2 pg/ml (2.4 – 7.4) 
1.67 ng/ml (1.47 – 1.99) 
 
 
0.01 μg/ml (0.00 – 0.06) 
3.2 pg/ml (2.4 – 5.8) 
1.59 ng/ml (1.45 – 1.85) 
 
 
0.01 
0.28 
0.23 
 
 
Oslo: 
MDAS 
Edinburgh: 
DRS-R98 
No 
comment on 
relationship 
between 
biomarkers 
Not 
measured 
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and delirium 
severity 
Hirsch et al(Hirsch 
et al., 2016) 
17 cytokines +  
Aβ42 and Aβ40 
IL-6, IL-8 and MCP-1 showed a persistent ↑ in the patient 
with delirium 
In all patients, several pro- and anti-inflammatory cytokines 
changed significantly postoperatively  
Changes for several biomarkers were more pronounced in 
CSF compared to plasma 
   Not 
measured 
Not 
measured 
Hall et al(Hall et 
al., 2016) 
Neopterin 
↑ Neopterin in delirium 
Neopterin highest in delirium superimposed on dementia 
Neopterin highest in incident delirium, followed by prevalent 
delirium, compared to subsyndromal or never delirium 
CSF neopterin correlated positively with delirium severity 
(MDAS) in group without prior cognitive impairment 
(Rho=0.42, p=0.04) 
29.6 nmol/ml (22.3 – 40.4) 24.7 nmol/ml (19.4 –30.6) 0.003 Oslo: 
MDAS 
Edinburgh: 
DRS-R98, 
MDAS 
rated 
retrospectiv
ely 
Not 
measured 
Hov et al(Hov et 
al., 2016)  
CSF/serum albumin 
ratio 
All 14 patients with blood-CSF barrier dysfunction had 
delirium (n=11) or subsyndromal delirium (n=3)  
Most patients with delirium had intact blood-CSF barrier 
   MDAS.  
No 
comment on 
relationship 
between 
biomarkers 
and delirium 
severity 
Not 
measured 
Poljak et al(Poljak 
et al., 2014) 
Proteomics 
Apolipoproteins, chromogranins and secretogranins 
downregulated in delirium 
α-2-macroglobulin, fibrinogen, α-1-antitrypsin, α-1-
antichymotrypsin, transferrin, complement component 3 and 
haptoglobin upregulated in delirium 
Upregulated α-1-glycoprotein in delirium, with ↑ levels in 
delirium vs. Alzheimer’s dementia confirmed by ELISA 
 
 
 
277.85μg/ml (19.51) 
 
 
 
207.44μg/ml (22.81) 
 
 
 
0.026 
Sydney: 
Delirium 
index 
Edinburgh: 
DRS-R98  
 
Not 
measured 
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Regression analysis did not find any significant association 
between proteins identified and delirium severity 
Westhoff et 
al(Westhoff et al., 
2015) 
Proteomics 
Proteomics revealed 8 proteins significantly different 
between delirium and no delirium in the derivation cohort 
None of the findings were confirmed with immunoassay in 
the validation cohort 
   Derivation 
study: not 
measured 
Validation 
cohort: 
DOSS but 
no comment 
on 
relationship 
Not 
measured 
End-products of delirium 
Study, 
biomarkers 
measured 
Main findings at baseline 
Direction of change Cases 
Mean (SD) or median (range) 
or (IQR) 
Controls 
Mean (SD) or median 
(range) or (IQR) 
p-value Delirium 
severity 
Delirium 
subtype 
Caplan et 
al(Caplan et al., 
2010) 
Lactate, NSE, 
S100B, Glucose, 
Protein 
In delirium vs. controls with Alzheimer’s dementia: 
↑ CSF lactate 
↓ CSF NSE 
↑ CSF protein 
S100B no different 
CSF lactate positively correlated with DI (r=0.703, p<0.001) 
CSF NSE positively correlated with DI (r= -0.467, p=0.014) 
 
1.87mmol/L (0.31) 
4.84ng/ml (2.02) 
0.62g/L (0.33) 
604.8pg/ml (163.0) 
 
1.48mmol/L (0.23) 
8.98ng/ml (2.98) 
0.44g/L (0.15) 
697.4pg/ml (306.9) 
 
<0.001 
<0.001 
0.036 
0.33 
Delirium 
index 
 
Comment 
that most 
patients had 
mixed 
subtype  
Hall et al(Hall et 
al., 2013) 
S100B 
↑ LogS100B in preoperative delirium 
 
-0.156 (0.238) 
 
-0.306 (0.162) 
 
0.035 
 
DRS-R98 
measured  
but no 
comment on 
relationship 
Not 
measured 
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Beishuizen et 
al(Beishuizen et al., 
2015) 
S100B  
No difference in S100B 
High S100B levels in the two patients with preoperative 
delirium 
1053  pg/ml (601 – 1178) 862 pg/ml (701 – 1177) 0.76 Not 
measured 
Not 
measured 
Table 2. Main findings of  included studies.  
5-HIAA - 5-Hydroxyindole-acetic acid. Aβ40 - Amyloid-β 1-40. Aβ42 - Amyloid-β 1-42. AChE - Acetyl-cholinesterase. BLI - Beta Endorphin-like immunoreactivity. DI – Delirium Index. 
DOSS – Delirium Observation Screening Scale. DRS – Delirium Rating Scale. DRS-R98 – Delirium Rating Scale Revised-98. GFAP - Glial Fibrillary Acidic Protein. HVA - Homovanillic acid. 
IL – interleukin. IFN-γ – Interferon gamma. IGF – insulin like growth factor. MCP - monocyte chemotactic protein. MDAS – Memorial Delirium Assessment Scale. MMSE – Mini-Mental State 
Examination. NSE - Neuron-specific enolase. P-tau - phosphorylated tau. S100B - S100 calcium-binding protein B. sIL-6R - soluble IL-6 receptor. SLI - Somatostatin-like immunoreactivity. 
TNF – tumor necrosis factor. T-tau – total tau.   
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Study Assessment of risk of bias Additional quality points 
Selection of 
participants 
Confounding 
variables 
(dementia) 
Measurement of 
exposure 
(delirium) 
Blinding of 
outcome 
assessments 
Incomplete 
outcome data 
Selective 
outcome 
reporting 
Power 
calcul-
ation 
Comments 
Koponen(Koponen 
et al., 1994c, 
Koponen et al., 
1994b, Koponen et 
al., 1994a, 
Koponen and 
Riekkinen, 1990) 
BLI, SLI, 5-HIAA, 
AChE 
Low 
Consecutive 
Low 
DSM III diagnosis 
and subtyping 
Low 
DSM III diagnosis 
High Low Low No Serum collected but not 
reported 
Ramirez-
Bermudez(Ramirez
-Bermudez et al., 
2008) 
HVA 
Low 
Consecutive 
 
High 
Young cohort, 
none with known 
diagnosis but no 
additional testing 
Low 
DSM IV 
diagnosis, DRS 
Low Low Low No Conference abstract suggests 
other biomarkers measured 
No paired serum 
Caplan(Caplan et 
al., 2010) 
S100B, NSE, 
protein, lactate 
High 
Enrolment offered 
on investigation 
for prolonged 
delirium on 
clinical grounds 
Low 
IQCODE. 
Low 
CAM, Delirium 
Index 
High Low Low No IQCODE comparable between 
groups, not used to stratify 
patients or adjust analyses 
Delirium: controls were stable 
AD out-patients with “no 
evidence of delirium”, no 
formal testing 
Paired serum 
Pearson(Pearson et 
al., 2010) 
Cortisol 
High 
Opportunistic 
High 
Documented 
dementia 
excluded, no 
High 
CAM, MDAS, DSI 
High Low Low No Paired serum 
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informant history 
or IQCODE 
MacLullich(MacLu
llich et al., 2011) 
IL-8 
High 
Opportunistic 
High 
Documented 
dementia 
excluded, no 
informant history 
or IQCODE 
Low 
CAM 
High Low Low No Paired serum 
Witlox(Witlox et 
al., 2011) 
β-amyloid, tau 
Low 
Consecutive 
Low 
IQCODE-N, 
MMSE 
 
Low 
CAM 
High Low Low No Patients part of negative clinical 
trial 
Patients with known dementia 
excluded 
No paired serum 
Hall(Hall et al., 
2013) 
S100B 
High 
Opportunistic 
Low 
IQCODE  
Low 
CAM, DRS-R98 
High Low Low No Lab researchers blinded to 
clinical data but not detailed in 
paper 
No paired serum 
Westhoff(Westhoff 
et al., 2013) 
Cytokines 
Low 
Consecutive 
Low 
IQCODE-N, 
MMSE 
Low 
CAM, DRS-R98 
High Low Low No Patients part of negative clinical 
trial 
Paired serum but different assay 
Cape(Cape et al., 
2014) 
IL-1β, IL-1ra 
High 
Opportunistic 
Low 
IQCODE for 2/3 
proportion 
Low 
DSM-IV using 
CAM 
High Low Low No Paired serum 
Poljak(Poljak et al., 
2014) 
Proteomics 
High 
Sydney: 
enrolment offered 
on investigation 
for prolonged 
Low 
IQCODE 
 
Low 
Sydney: CAM, DI 
Edinburgh: CAM, 
DRS-R98 
High Low Low No Selective outcome reporting; 
proteomics analysis, so may not 
discuss all results 
No paired serum 
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delirium on 
clinical grounds 
Edinburgh: 
opportunistic 
Watne(Watne et al., 
2014) 
Anticholinergic 
activity 
High 
Oslo: consecutive 
Edinburgh: 
opportunistic  
Low 
IQCODE 
Low 
CAM, MDAS 
(retrospective in 
Edinburgh from 
DRS-R98) 
Low Low Low No Oslo patients part of negative 
clinical trial 
Paired serum; discrepancy in 
serum AA levels 
Xie(Xie et al., 
2014) 
β-amyloid, tau 
Low 
Consecutive 
High 
Documented 
dementia 
excluded, no 
informant history 
or IQCODE 
Low 
CAM, MDAS 
High Low Low Yes No paired serum 
Beishuizen(Beishui
zen et al., 2015) 
S100B  
Unclear 
 
Low 
IQCODE 
Unclear 
DSM IV diagnosis 
from medical 
records, ?no 
formal testing 
High Low Low No No paired serum 
Westhoff(Westhoff 
et al., 2015) 
Proteomics 
Low 
Consecutive 
Low 
IQCODE 
Low 
Derivation 
cohort: CAM 
Validation cohort: 
DOSS followed by 
DSM IV diagnosis 
by psychiatrist 
Low Low Low No Selective outcome reporting; 
proteomics analysis, so may not 
discuss all results 
Derivation cohort part of 
negative clinical trial 
Preoperative delirium excluded 
No paired serum 
Hall(Hall et al., 
2016) 
High 
Oslo: consecutive 
Low 
IQCODE 
Low 
CAM, MDAS 
(retrospective in 
Low Low Low No Oslo patients part of a negative 
clinical trial 
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Neopterin Edinburgh: 
opportunistic 
Edinburgh from 
DRS-R98) 
Paired serum 
Hirsch(Hirsch et 
al., 2016) 
Cytokines 
High 
Opportunistic 
High 
Impaired 
cognition 
excluded, no 
inforrmant history 
or IQCODE 
Low 
CAM 
High Low Low No Only n=1 with delirium (pilot 
study) 
Paired serum 
Hov(Hov et al., 
2016) 
BBB 
Low 
Consecutive 
Low 
Dementia status 
according to 
consensus of an 
expert panel 
Low 
CAM, MDAS 
Low Low Low No Patients part of a negative 
clinical trial 
Paired serum 
Neerland(Neerland 
et al., 2016) 
IL-6, CRP 
High 
Oslo: consecutive 
Edinburgh: 
opportunistic 
Low 
IQCODE 
Low 
CAM, MDAS 
(retrospective in 
Edinburgh from 
DRS-R98) 
Low Low Low No Oslo patients part of negative 
clinical trial 
Paired serum 
Watne(Watne et al., 
2016) 
Aromatic amino 
acids 
High 
Consecutive 
recruitment but 
groups selected 
Low 
Dementia status 
according to 
consensus of an 
expert panel 
Low 
CAM 
Low Low Low No Patients part of a negative 
clinical trial 
Paired serum 
Idland(Idland et al., 
2016) 
Amyloid, tau 
Low 
Consecutive 
Low 
Dementia status 
according to 
consensus of an 
expert panel 
Low 
CAM 
Low Low Low No Patients part of a negative 
clinical trial 
No paired serum 
Table 3 Summary of assessment of risk of bias and additional comments on study quality 
5-HIAA - 5-Hydroxyindole-acetic acid. AA - Anticholinergic Activity. AChE - Acetyl-cholinesterase. AD – Alzheimer’s Dementia. BBB – blood-brain barrier. BLI - Beta Endorphin-like 
immunoreactivity. CAM – Confusion Assessment Method. DOSS - Delirium Observation Screening Scale. DRS-R98– Delirium Rating Scale – Revised. DSM - Diagnostic and Statistical 
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Manual of Mental Disorders. HVA - Homovanillic acid. IL – interleukin. IQCODE - Informant Questionnaire on Cognitive. Decline in the Elderly. MDAS – Memorial Delirium Assment Scale. 
NSE - Neuron-specific enolase. S100B - S100 calcium-binding protein B. SLI - Somatostatin-like immunoreactivity.  
 
 
Planning and consent Proposals, information sheets and consent forms should be written to allow for future collaborations 
between centres, including transfer to and storage and analysis of samples within another centre, and 
future biomarker analyses. Broad and enduring consent is essential. 
Governance 
 
Local legal arrangements for sample storage needs to be considered and time permitted for Material 
Transfer Agreements and Collaboration Agreements to be drawn up 
CSF collection, handling and storing Freezer space needs to be planned in advance. Collection volumes and collection container type and 
volume, storage aliquot volumes and container type and size should be decided in advance. Aliquot 
volumes, and sample organisation, should be considered in advance aiming to minimise freeze-thaw 
cycles. Sample transfer to the laboratory for processing should be as swift as possible, and ideally 
within 2 hours. A potential centrifugation protocol of 2000g, for 10 minutes, at room temperature 
could be considered. Samples should be stored at -80°C. Polypropylene tubes are recommended and 
efforts should be made to use the same brand of containers throughout. Transfer methods, eg dry ice 
and courier services, may also need considered. 
Blood samples Ideally matched serum/plasma and DNA samples should be collected alongside CSF samples.  
Reporting 
 
Methods used should be consistent and explicitly reported.  
Specifically, time of day, fasting status, needle used, volume and material of collection vessels used, 
including manufacturer, method of sampling ie aspiration vs drop collection, volume of CSF collected, 
time and temperature to centrifugation, centrifugation details, storage vessel used, aliquot volume, 
storage temperature and number of freeze-thaw cycles should be reported. Ideally coefficients of 
variation should be reported. 
Collection of clinical data Reliable and valid delirium assessment against standard criteria using a validated tool is essential, with 
a preference for collecting additional detail: cognitive testing with reporting of scores and/or 
untestability; level of arousal measurement; assessment of psychotic features and motoric status; 
documentation of presumed aetiologies including potential drug toxicity; assessment of delirium 
severity. Information regarding dementia status is particularly important. In elective studies, patients 
should undergo objective cognitive testing before sampling of CSF. In studies recruiting acutely 
admitted patients, questionnaires such as the Informant Questionnaire on Cognitive Decline in the 
Elderly (IQCODE) can be used to assess dementia status.  
Table 4. Recommendations for future CSF studies in delirium.  
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Figure 1 
 
Additional records identified 
through other sources 
N=96 
Records after duplicates removed 
N=2352 
Studies included in 
qualitative synthesis N=22 
Records identified through 
database searching 
N=3184 
Studies suitable for 
inclusion 
N=26 
Duplicate sequential 
reports, exclude older 
papers N=4 
Records excluded  
N=2158 
Records screened 
N=2352 
Full text articles 
assessed for eligibility 
 
N=194 
Full text articles excluded = 168 
Case reports N=6 
Delirium Tremens or alcohol-related N=10 
Delirium not appropriately diagnosed N=12 
Reviews N=29 
Short conference abstract N=17 
Serum study N=8 
Animal study N=1 
Study not available in English N=4 
Study discussing appropriateness of LP in clinical setting N=3 
No diagnosis of delirium made N=39 
Mixed Neuropsychiatric SLE, no identifiable delirium subgroup N=31 
Delirium secondary to SLE and other causes excluded N=8 
